6855.HK
C-MER swings to the red

Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas IPO. The company plans to list on the Nasdaq and issue up to 33.7 million common shares, according to the CSRC’s announcement of the listing’s official registration.

In June this year, Ascentage Pharma, which is already listed in Hong Kong, announced that Japan’s Takeda Pharmaceutical (4502.T) invested $75 million for 7.73% of Ascentage, becoming its second-largest shareholder. Takeda also get an exclusive option to develop and market the Ascentage’s olverembatinib drug outside of China and Russia, for an initial payment of $100 million.

After confirming its receipt of Takeda’s payment, Ascentage reported a net profit of 163 million yuan ($22.3 million) in the first half of 2024, representing its first profit since its establishment in 2009. Its revenue for the period rose 477% year-on-year to 824 million yuan.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

an Illustration of McKinsey weighing China exit

McKinsey Weighs China Exit, and Shenzhen Rescues Vanke

Some partners at U.S. consulting giant McKinsey are questioning the wisdom of staying in China. What's driving their doubt, and what would a withdrawal signify? And Shenzhen rescues struggling developer Vanke. What is the city demanding in return for its assistance?
Huawei stages improbable comeback

Huawei rings up improbable comeback as revenue soars

The Shenzhen-based telecoms giant said its revenue rose 22% in 2024, showing that years of U.S. sanction have failed to contain its rise Key Takeaways: Huawei reported its second-highest annual…
Sands China’s revenue growth losing momentum in the fourth quarter amid gaming revenue weakness in Macao

Lady luck looks away from Sands China

The casino operator’s revenue declined in last year’s fourth quarter as the Macao gaming sector’s post-pandemic rebound lost steam Key Takeaways: Sands China reported its revenue fell 5% year-on-year in…